



US008071648B2

(12) **United States Patent**
Wong

(10) **Patent No.:** **US 8,071,648 B2**
(45) **Date of Patent:** ***Dec. 6, 2011**

(54) **TOPICAL NEPAFENAC FORMULATIONS**
(75) Inventor: **Warren Wong**, Fort Worth, TX (US)
(73) Assignee: **Novartis AG**, Basel (CH)
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
This patent is subject to a terminal disclaimer.

4,851,443 A 7/1989 Brune
4,910,225 A 3/1990 Ogawa et al.
5,073,641 A 12/1991 Bundgaard et al.
5,461,081 A 10/1995 Ali et al.
5,475,034 A 12/1995 Yanni et al.
5,521,222 A 5/1996 Ali et al.
5,624,893 A 4/1997 Yanni
6,342,524 B1 1/2002 Hellberg et al.
6,638,976 B2 10/2003 Gamache et al.
2002/0037929 A1 3/2002 Kapin et al.
2003/0207941 A1 11/2003 Bingaman et al.
2005/0239895 A1 10/2005 Sawa et al.

(21) Appl. No.: **12/888,631**
(22) Filed: **Sep. 23, 2010**

GB 2071086 9/1981
GB 2093027 8/1982
WO WO0213805 A2 2/2002
WO WO03092669 A2 11/2003

(65) **Prior Publication Data**
US 2011/0015271 A1 Jan. 20, 2011

FOREIGN PATENT DOCUMENTS

Related U.S. Application Data

(63) Continuation of application No. 11/292,484, filed on Dec. 2, 2005, now Pat. No. 7,834,059.
(60) Provisional application No. 60/632,562, filed on Dec. 2, 2004.

OTHER PUBLICATIONS

L. F. Sancilio, et al., "AHR-10037, a Non-Steroidal Anti-Inflammatory Compound of Low Gastric Toxicity," Agents and Actions, 1990, pp. 177-126, vol. 31.
Tai-Lee Ke, et al., "Nepafenac, a Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: II. In Vitro Bioactivation and Permeation of External Ocular Barriers," Inflammation, 2000, pp. 371-384, vol. 24(4).
David A. Walsh, et al., "Antiinflammatory Agents. 3. Syntheses and Pharmacological Evaluation of 2-Amino-3-Benzoylphenylacetic Acid and Analogues," J. Med. Chem., 1984, pp. 1379-1388, vol. 27(11).
David A. Walsh, et al., "Antiinflammatory Agents. 4. Synthesis and Biological Evaluation of Potential Prodrugs of 2-Amino-3-Benzoylbenzeneacetic Acid and 2-Amino-3-(4-Chlorobenzoyl)Benzeneacetic Acid," J. Med. Chem., 1990, pp. 2296-2304, vol. 33.
J. S. Penn, et al., "Studies of the Effect and Mechanism of Action of Topical Nepafenac in a Rat Model of ROP," ARVO Annual Meeting, Fort Lauderdale, Florida, May 5-10, 2002, Abstract 2741.

(51) **Int. Cl.**
A61K 31/195 (2006.01)
(52) **U.S. Cl.** **514/567**; 424/486
(58) **Field of Classification Search** 514/567
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,828,093 A 8/1974 Bays et al.
4,045,576 A 8/1977 Welstead, Jr. et al.
4,126,635 A 11/1978 Welstead, Jr. et al.
4,182,774 A 1/1980 Welstead, Jr. et al.
4,254,146 A 3/1981 Walsh
4,313,949 A 2/1982 Shanklin, Jr. et al.
4,503,073 A 3/1985 Walsh et al.
4,568,695 A 2/1986 Moran et al.
4,683,242 A 7/1987 Poser
4,783,487 A 11/1988 Brune

Primary Examiner — Jake M. Vu
(74) *Attorney, Agent, or Firm* — Patrick M. Ryan

(57) **ABSTRACT**

Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.

1 Claim, No Drawings